|
Viva Biotech, a leading contract research organization (CRO), optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to accelerate the discovery of novel therapeutics with AI-driven designs with NVIDIA technology.
The collaboration highlights Viva Biotech's “Lab-in-the-Loop” workflow, combining de novo computational design with high throughput protein production and biophysical evaluation to design ActRIIA binders. This integrated approach demonstrates how in silico predictions with real-world experimental validations can expedite drug discovery, showcasing the effectiveness of NVIDIA BioNeMo and Viva Biotech's AI-driven integrated drug discovery platform in optimizing drug candidates.
As part of this effort, Viva Biotech leverages its AI technique for sequence selection and provide valuable feedback to improve the original Proteina-Complexa model. This iteration led to more efficient and targeted mini-binder designs. Guided by AI-driven insights, we successfully explored previously uncharted chemical space and significantly enhanced design specificity, achieving these advances at a fraction of the cost and time compared with conventional drug candidate nomination processes.
As a leading contract research organization (CRO) that specializes in AI-driven drug discovery (AIDD) and structure-based drug discovery (SBDD), Viva Biotech combines computational modelling, generative AI, and extensive wet lab capabilities to accelerate the discovery of small molecules, antibodies, peptides, fusion proteins, PROTACs, molecular glues, and RNA-targeting compounds.
|